RT Journal Article
SR Electronic
T1 Synchronized travel restrictions across cities can be effective in COVID-19 control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.02.20050781
DO 10.1101/2020.04.02.20050781
A1 Haiyan Liu
A1 Xuemei Bai
A1 Huanfeng Shen
A1 Xiaoping Pang
A1 Zeyu Liang
A1 Yue Liu
YR 2020
UL http://medrxiv.org/content/early/2020/04/12/2020.04.02.20050781.abstract
AB The COVID-19 outbreak is under control in China. Mobility interventions, including both the Wuhan lockdown and travel restrictions in other cities, have been undertaken in China to mitigate the epidemic. However, the impact of mobility restrictions in cites outside Wuhan has not been systematically analyzed. Here we ascertain the relationships between all mobility patterns and the epidemic trajectory in Chinese cities outside Hubei Province, and we estimate the impact of local travel restrictions. We estimate local inter-city travel bans averted 22.4% (95% PI: 16.8–27.9%) more infections in the two weeks after the Wuhan lockdown, while local intra-city travel prevented 32.5% (95% PI: 18.9–46.1%) more infections in the third and fourth weeks. More synchronized implementation of mobility interventions would further decrease the number of confirmed cases in the first two weeks by 15.7% (95% PI:15.4–16.0%). This study shows synchronized travel restrictions across cities can be effective in COVID-19 control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementIndependent research fund of Wuhan UniversityAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collated epidemiological data and mobility data from publicly available data sources. All the data sources we used are documented in the main text and supplementary tables.